Literature DB >> 6296291

Vesicular stomatitis virus can establish persistent infections in Syrian hamsters.

P N Fultz, J A Shadduck, C Y Kang, J W Streilein.   

Abstract

Persistent infections by vesicular stomatitis virus (VSV) of the Indiana serotype were readily established in adult Syrian hamsters following intraperitoneal injection of the virus. Plaque-forming virus, identified as VSV by serological and physical criteria, was isolated from brain homogenates of five hamsters that were tested 3 to 8 months after infection. Four of these animals had exhibited either transient or permanent paralysis, whereas the fifth appeared healthy, during the period of observation. At the time of sacrifice all hamsters had high titres of anti-VSV-neutralizing antibodies in their sera.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6296291     DOI: 10.1099/0022-1317-63-2-493

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

Review 1.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

2.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

3.  Pathogenesis of mucosal disease: a cytopathogenic pestivirus generated by an internal deletion.

Authors:  N Tautz; H J Thiel; E J Dubovi; G Meyers
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

4.  rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

Authors:  Thomas P Monath; Patricia E Fast; Kayvon Modjarrad; David K Clarke; Brian K Martin; Joan Fusco; Richard Nichols; D Gray Heppner; Jakub K Simon; Sheri Dubey; Sean P Troth; Jayanthi Wolf; Vidisha Singh; Beth-Ann Coller; James S Robertson
Journal:  Vaccine X       Date:  2019-01-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.